[BREAKING] AstraZeneca COVID-19 Vaccine Begins Final Trials; The US Government Orders 100 Million Doses

0

AstraZeneca will now begin the Oxford University coronavirus vaccine’s final trials. The United States government has contributed $1.2 billion or £910m to the research and development of the vaccine.  

Also Read: New Study Shows Early Death Increased by 30% When Taking Naps Longer Than One Hour, And May Lead to Heart Disease

The U.K. drug giant AstraZeneca enrolled 30,000 American volunteers in phase three clinical trial. A total of 50,000 people across the globe will participate in the vaccine’s final tests.

Also Read: LG’s Wearable Air Purifier ‘Puricare’ Mask is Pretty But Does Not Help During COVID-19 Pandemic – Reports

In the United Kingdom, South Africa, and Brazil, thousands of people were already injected with the experimental drug and are being monitored by medical experts.

Sarah Gilbert, Oxford’s Professor behind the vaccine’s development, said that the preliminary data from trials in the countries that already received the medicine could be expected in the coming weeks.

Scientists from Oxford and AstraZeneca promised that the drug would be delivered to the countries most vulnerable to COVID-19, by the end of the year. One of these countries is Russia, where millions are infected, and Japan, where a deadly second wave occur.

AstraZeneca has made a deal of $20 million (£15million) with Oxford Biomedica, a gene, and therapy firm, which will be the primary manufacturer of the vaccine for 18 months in Britain.

The British drugmaker also made deals with China and across Europe, hoping to supply countries worldwide with the Oxford vaccine.

Brazil

Brazilian government ordered 100 million doses of the experimental drug, setting aside $360 million or £274m. The country has 3.6 million official cases and 114,000 deaths currently.

Australia 

Australian officials said that the country ordered enough doses for 25 million people. However, the exact amount of medicine was not disclosed.

China 

Shenzhen Kangtai Biological Products, a Chinese company based in Shenzhen, has agreed on a deal with AstraZeneca to manufacture 100 million doses of the vaccine. By the end of 2021, the company will increase its capacity to 200 million doses every year.

For more news updates about AstraZeneca’s COVID-19 vaccine, always keep your tabs open here at TechTimes. 

Also Read: BEWARE: Extensive Use of Hand Sanitizers May Trigger Superbug ‘Armageddon’ -Expert Warns

This article is owned by TechTimes,

Written by: Giuliano de Leon.

Share.

About Author

Leave A Reply